All In Biotech

Drug Trial Radar · NCT07923071

A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment

A Phase 1, Open-label, Parallel Group Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Relapsed/Refractory Hematologic Malignancies and Severe Hepatic or Renal Impairment or Normal Hepatic and Renal Function

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2030

Study completion Jan 2032

Sponsor

Lead sponsor
Syndax PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to characterize the pharmacokinetic (PK) parameters of revumenib and its major metabolite, N-deethyl revumenib (M1) after a single dose of revumenib in participants with severe liver or kidney impairment or normal liver and kidney function.

Conditions

  • Relapsed/Refractory (R/R) Hematologic Malignancies
  • Acute Leukemia
  • Refractory Leukemia
  • Relapsed Leukemia

Interventions

  • RevumenibDrug

    Administered as oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of RevumenibTime frame: Up to 1 day postdose
  2. Area Under the Concentration-Time Curve From Time 0 to 24 hours (AUC0-24) of M1Time frame: Up to 1 day postdose
  3. Maximum Observed Concentration (Cmax) of RevumenibTime frame: Up to 1 day postdose
  4. Maximum Observed Concentration (Cmax) of M1Time frame: Up to 1 day postdose
  5. Terminal Elimination Half-Life (t1/2) of RevumenibTime frame: Up to 1 day postdose
  6. Terminal Elimination Half-Life (t1/2) of M1Time frame: Up to 1 day postdose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.